Analysts Set DENTSPLY SIRONA Inc. (NASDAQ:XRAY) PT at $13.82

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has been given a consensus rating of “Hold” by the fourteen brokerages that are currently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $13.8182.

XRAY has been the topic of a number of analyst reports. Robert W. Baird lifted their target price on shares of DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a research report on Friday, February 27th. Zacks Research raised DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research note on Monday, March 2nd. Bank of America upgraded DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $13.00 to $17.00 in a report on Thursday, February 19th. Wells Fargo & Company boosted their target price on DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a research note on Friday, February 27th. Finally, Weiss Ratings cut DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th.

Insider Activity at DENTSPLY SIRONA

In other news, Director James D. Forbes bought 5,000 shares of the business’s stock in a transaction dated Monday, March 9th. The shares were purchased at an average price of $12.48 per share, for a total transaction of $62,400.00. Following the completion of the acquisition, the director owned 10,000 shares of the company’s stock, valued at approximately $124,800. This trade represents a 100.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Gregory T. Lucier bought 15,000 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The stock was purchased at an average cost of $12.45 per share, for a total transaction of $186,750.00. Following the completion of the purchase, the director owned 65,000 shares of the company’s stock, valued at $809,250. This trade represents a 30.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired 42,445 shares of company stock valued at $564,053 in the last quarter. Corporate insiders own 0.46% of the company’s stock.

Institutional Investors Weigh In On DENTSPLY SIRONA

A number of large investors have recently added to or reduced their stakes in XRAY. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of DENTSPLY SIRONA in the first quarter valued at about $26,000. Goldman Sachs Group Inc. grew its stake in shares of DENTSPLY SIRONA by 827.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after purchasing an additional 2,172,343 shares during the last quarter. Empowered Funds LLC grew its stake in shares of DENTSPLY SIRONA by 8.8% in the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock worth $244,000 after purchasing an additional 1,320 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in DENTSPLY SIRONA by 7.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock valued at $8,860,000 after purchasing an additional 41,579 shares during the period. Finally, Focus Partners Wealth increased its holdings in DENTSPLY SIRONA by 59.1% during the 1st quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock valued at $376,000 after purchasing an additional 9,355 shares during the period. Institutional investors own 95.70% of the company’s stock.

DENTSPLY SIRONA Price Performance

Shares of XRAY opened at $10.47 on Monday. The firm has a market cap of $2.10 billion, a P/E ratio of -3.32, a P/E/G ratio of 1.24 and a beta of 0.89. The stock has a 50 day simple moving average of $11.26 and a two-hundred day simple moving average of $11.75. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.53 and a quick ratio of 0.98. DENTSPLY SIRONA has a 1 year low of $9.40 and a 1 year high of $17.09.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The business had revenue of $880.00 million for the quarter, compared to the consensus estimate of $841.80 million. DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The firm’s revenue was up .1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.43 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, analysts forecast that DENTSPLY SIRONA will post 1.42 earnings per share for the current fiscal year.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.